| Literature DB >> 29751811 |
Elham Shabani Varaki1, Gaetano D Gargiulo2, Stefania Penkala3, Paul P Breen2,4.
Abstract
BACKGROUND: Worldwide, at least 200 million people are affected by peripheral vascular diseases (PVDs), including peripheral arterial disease (PAD), chronic venous insufficiency (CVI) and deep vein thrombosis (DVT). The high prevalence and serious consequences of PVDs have led to the development of several diagnostic tools and clinical guidelines to assist timely diagnosis and patient management. Given the increasing number of diagnostic methods available, a comprehensive review of available technologies is timely in order to understand their limitations and direct future development effort. MAIN BODY: This paper reviews the available diagnostic methods for PAD, CVI, and DVT with a focus on non-invasive modalities. Each method is critically evaluated in terms of sensitivity, specificity, accuracy, ease of use, procedure time duration, and training requirements where applicable.Entities:
Keywords: Ankle Brachial Index; Chronic venous insufficiency; Deep vein thrombosis; Doppler ultrasound; Peripheral arterial disease; Plethysmography
Mesh:
Year: 2018 PMID: 29751811 PMCID: PMC5948740 DOI: 10.1186/s12938-018-0494-4
Source DB: PubMed Journal: Biomed Eng Online ISSN: 1475-925X Impact factor: 2.819
Fig. 1Examples of peripheral vascular function assessment in the lower limb using plethysmography techniques; a strain gauge plethysmography [37]; b photo plethysmography (PPG); c quantitative PPG/light reflection rheography (LRR); d Impedance Plethysmography, modified from [38]; e Air Plethysmography (APG) [39]
Computerized strain-gauge plethysmography reference values for controls and patients with DVT.
from [42]
| Venous parameter | Control (mean and 95% confidence interval) | Patients with DVT (mean and 95% confidence interval) |
|---|---|---|
| Venous emptying (mL/100 mL × min) | 84 | 110 |
| Venous outflow rate | 0.58 | 0.76 |
| Half refilling time (S) | 6 | 17 |
| Venous refilling volume (mL/100 mL) | 1.11 | 1.65 |
Sensitivity and Specificity evaluation for the use of photo-plethysmography (PPG) in the diagnosis of PVDs
| Study | Diagnosis target | Reference method | N (control/patient) | PPG feature | Sensitivity | Specificity |
|---|---|---|---|---|---|---|
| Allen et al. [ | PAD | ABI | 107 (63/44) | PPG waveform | 90.6% | 88.9% |
| Ro et al. [ | PAD | Angiography | 194a (31/163) | PPG waveform | 81.6% | 77.4% |
| Bays et al. [ | CVI | Duplex ultrasound | 20 (10/10) | PPG refill time (venous refill time) | 100% | 60% |
| Sarin et al. [ | CVI | Duplex scanning | 304a (80/224) | PPG refill time (venous refill time) | 74–79% | 61% |
| Mitrani et al. [ | DVT | Venography | 69 (45/24) | Venous emptying (threshold 3 mm) | 96% | 71% |
| Venous emptying (threshold 6 mm) | 86% | 89% | ||||
| Venous emptying rate (threshold 0.17 mm/s) | 83% | 89% | ||||
| Venous emptying rate (threshold 0.31 mm/s) | 96% | 78% | ||||
| Arora et al. [ | DVT | Venography | 69a (41/28) | Venous Emptying Rate (threshold 0.35 mm/s) | 96.4% | 82.9% |
| Thomas et al. [ | DVT | Venography | 131a (61/70) | Shape of PPG trace | 92% | 84% |
| Tan et al. [ | DVT | Venography or duplex | 103a (66/37) | Venous refilling time (threshold 20 s) | 100% | 47% |
| Venous refilling time (threshold 36 s) | 100% | 35% | ||||
| Venous refilling time and venous pump | 100% | 56% |
“Control” refers to the number of the subjects diagnosed without PVD by the reference method
“Patient” refers to the number of the subjects diagnosed with PVD by the reference method
aDenotes the number of the limbs used in the study and not the number of subjects
Fig. 2Schematic view of the use of impedance plethysmography for detection of DVT
(adapted from [36])
Selection of studies using plethysmography methods in the diagnosis of PVDs
| Study | Diagnosis target | Reference method | Number of subjects (control/patient) | Plethysmography method | Sensitivity | Specificity |
|---|---|---|---|---|---|---|
| Harada et al. [ | CVI | Venography | 31a (0/31) | APG | 73% | 100% |
| Criado et al. [ | CVI | Duplex scanning and venography | 186a (61/125) | APG | 80% | 94% |
| Bays et al. [ | CVI | Duplex ultrasound | 20a (10/10) | APG | 70%–100% | 90%–100% |
| Rosfors et al. [ | Venous disorder (CVI, DVT) | Duplex ultrasound | 119 (63/56) | SGP | 96%–98% | Not given |
| Allen et al. [ | PAD | ABI | 107 (63/44) | PPG | 90.6%, | 88.9% |
| Ro et al. [ | PAD | Angiography | 194a (31/163) | PPG | 81.6% | 77.4% |
| Bays et al. [ | CVI | Duplex ultrasound | 20a (10/10) | PPG | 100% | 60% |
| Sarin et al. [ | CVI | Duplex scanning | 304a (80/224) | PPG | 74–79% | 61% |
| Mitrani et al. [ | DVT | Venography | 69 (45/24) | PPG | 83%–96% | 71%–89% |
| Arora et al. [ | DVT | Venography | 69a (41/28) | PPG | 96.4% | 82.9% |
| Thomas et al. [ | DVT | Venography | 131a (61/70) | PPG | 92% | 84% |
| Tan et al. [ | DVT | Venography or duplex | 103a (66/37) | PPG | 100% | 35%–56% |
| Anderson [ | PAD | Angiography | 61a (28/33) | IPG | > 90% | >90% |
| Mašanauskienė et al. [ | PAD | ABI | 62 (21/41) | IPG | 73.2% | 96% |
| Hull et al. [ | DVT | Venography | 200 (114/86) | IPG | 94% | 91% |
| Toy et al. [ | DVT | Venography | 25a (9/16) | IPG | 94% | 100% |
| Flanigan et al. [ | DVT | Venography | 207a (136/71) | IPG | 90.4% | 75.7% |
| Cooperman et al. [ | DVT | Venography | 98a (75/23) | IPG | 87% | 96% |
| Liapis et al. [ | DVT | Venography | 308a (169/139) | IPG | 91% | 89% |
| Peters et al. [ | DVT | Venography | 185 (124/61) | IPG | 84% | 93% |
| Cruickshank et al. [ | DVT | Venography | 1010a (812/198) | IPG | 12.9% | 98.1% |
| Paiement et al. [ | DVT | Venography | 937a (864/73) | IPG | 12.3% | 99.1% |
| Agnelli et al. [ | DVT | Venography | 440a (295/145) | IPG | 19% | 91% |
“Control” refers to the number of the subjects diagnosed without PVD by the reference method
“Patient” refers to the number of the subjects diagnosed with PVD by the reference method
aDenotes the number of the limbs used in the study and not the number of subjects
Selected studies using Doppler ultrasound methods in diagnosis of PVDs
| Study | Diagnosis target | Reference method | Number of subjects (control/patient) | Doppler ultrasound method | Sensitivity (%) | Specificity (%) |
|---|---|---|---|---|---|---|
| Dauzat et al. [ | DVT | Venography | 145 (45/100) | B-mode | 94 | 100 |
| Sullivan et al. [ | DVT | Venography | 23a (12/11) | B-mode | 100 | 92 |
| O’Leary et al. [ | DVT | Venography | 50 (25/25) | B-mode | 88 | 96 |
| Cronan et al. [ | DVT | Venography | 51 (23/28) | Duplex | 89 | 100 |
| Aly et al. [ | PAD | Angiography | 177a,b | Duplex | 92 | 99 |
| Linke et al. [ | PAD | Angiography | 46a,b | Duplex | 89 | 95 |
| Bergamini et al. [ | PAD | Angiography | 80a (28/52) | Duplex | 80 | 95 |
| Eiberg et al. [ | PAD | Angiography | 169 (0/169) | Duplex | 88 | 79 |
| Whelan et al. [ | Arterial occlusion | Angiography | 51 (8/43) | Duplex | 95 | 99 |
| Whelan et al. [ | Arterial stenosis | Angiography | 51 (8/43) | Duplex | 92 | 97 |
“Control” refers to the number of the subjects diagnosed without PVD by the reference method
“Patient” refers to the number of the subjects diagnosed with PVD by the reference method
aDenotes the number of the limbs used in the study and not the number of subjects
bComparison between limb segments and not control/patients
Selected studies using blood pressure measurement methods in diagnosis of PVDs
| Study | Diagnosis target | Reference method | Number of subjects (control/patient) | Blood pressure measurement method | Sensitivity | Specificity |
|---|---|---|---|---|---|---|
| Vega et al. [ | PAD | Angiography | 158a (27/131) | ABI | 95%–97% | 56%–89% |
| Wikström et al. [ | PAD | Angiography | 533a (421/112) | ABI | 15%–20% | 99% |
| Parameswaran et al. [ | PAD | Doppler waveform analysis | 114a (79/35) type 2 diabetes | ABI | 63% | 97% |
| Lijmer et al. [ | PAD | Angiography | 106a (0/106) | ABI | 79% | 96% |
| Schröder et al. [ | PAD | Duplex Ultrasound | 216 (103/113) | ABI | 68% | 99% |
| Niazi et al. [ | PAD | Angiography | 208a (42/166) | ABI | 68% | 83% |
| Guo et al. [ | PAD | Angiography | 298 (277/21) | ABI | 91% | 86% |
| Premalatha et al. [ | PAD | Duplex ultrasound | 94 (26/68) type 2 diabetes | ABI | 70.6% | 88.5% |
| Williams et al. [ | PAD | Duplex ultrasound | 41a (27/14) | ABI | 83% | 100% |
| Williams et al. [ | PAD | Duplex ultrasound | 32a (25/7) Diabetes | ABI | 100% | 88% |
| Williams et al. [ | PAD | Duplex ultrasound | 57a (41/16) Diabetes with neuropathy | ABI | 53% | 95% |
| Williams et al. [ | PAD | Duplex ultrasound | 41a (27/14) | TBI | 100% | 81% |
| Williams et al. [ | PAD | Duplex ultrasound | 32a (25/7) Diabetes | TBI | 91% | 65% |
| Williams et al. [ | PAD | Duplex ultrasound | 57a (41/16) Diabetes with neuropathy | TBI | 100% | 61% |
| Park et al. [ | PAD | Angiography | 30a (17/13) (Diabetes gangrene) | TBI | 100% | 100% |
“Control” refers to the number of the subjects diagnosed without PVD by the reference method
“Patient” refers to the number of the subjects diagnosed with PVD by the reference method
aDenotes the number of the limbs used in the study and not the number of subjects
Fig. 3VOTI system and its sandal shaped measuring probe [165]
Fig. 4HeMo prototype; a a demonstration of HeMo worn on the calf [166]; b HeMo cuff (adopted from [166]); c diagram of HeMo worn on the calf (adopted from [166]); d blood flow variations recorded before, during and after tiptoe exercise by HeMo [167]
Fig. 5Advent of milestone technologies for noninvasive diagnosis of PVDs